the glimmering light is someone paying that kind of money for the pipeline and status ie phase 1a 1b etc. And the IP seems to have kept a low profile given it was a private company. wonder how many players were playing to get to those numbers. i would be surprised if someone paying that much for the pipeline in early stages would stretch if not a competitive situation
just wondering how abbvie came about and whether genentech was a player.... looks like someone with last name g worked there and genentech at same time...
if i was running the show at pphm i would be dancing with azn but have one more forever hold your peace talks with a peek at sunrise data... imo it should be change of control time or get the tech in more capable hands....
"In a capital intensive industry like biotech, a check of a few million does very little. An investment of $300 million, however, can significantly speed the development of potentially life-saving drugs," Singerman wrote in a blog post about the acquisition. "Much as the reusable rocket ship wasn’t built by accident, the cure for cancer won’t come about by chance. Feats of this magnitude require complex coordination and meaningful amounts of capital."
pphm has been going the IST take your time approach...
News 
Market Data 
Discover 
AI
